Loading...
•
Mar 31, 2022
Atara Q1 2022 Earnings Report
Atara reported financial results for the first quarter of 2022 and provided recent business highlights.
Key Takeaways
Atara Biotherapeutics reported a net loss of $88.1 million, or $0.87 per share, for the first quarter of 2022. As of March 31, 2022, cash, cash equivalents, and short-term investments totaled $301.8 million, excluding the $100 million upfront payment from FUJIFILM Diosynth Biotechnologies (FDB) received in April.
Anticipated European Commission approval for Tab-cel remains on track for Q4 2022, with ongoing dialogue with the FDA.
Cash, cash equivalents and short-term investments totaled $301.8 million as of March 31, 2022.
FDA Fast-Track Designated ATA188 interim analysis on-track for June 2022.
Cash is expected to fund planned operations into Q4 2023, following the sale of the cell therapy manufacturing facility to FUJIFILM for $100 million.
Forward Guidance
Atara believes that its cash as of March 31, 2022, together with the $100.0 million received from FDB on April 4, 2022, will be sufficient to fund the Company’s planned operations into the fourth quarter of 2023
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...